Mass General: Strong, Durable Responses to Selpercatinib in RET-Driven Medullary Thyroid Cancer
August 29, 2020
August 29, 2020
BOSTON, Massachusetts, Aug. 29 -- Massachusetts General Hospital issued the following news release:
Selpercatinib (Retevmo), a drug targeted precisely against cancers driven by mutations or alterations in the gene RET, was effective in a clinical trial at shrinking tumors in patients with medullary thyroid cancer, with a majority of patients living for more than a year without disease progression.
The drug was effective both in patients with no prior treatment with targ . . .
Selpercatinib (Retevmo), a drug targeted precisely against cancers driven by mutations or alterations in the gene RET, was effective in a clinical trial at shrinking tumors in patients with medullary thyroid cancer, with a majority of patients living for more than a year without disease progression.
The drug was effective both in patients with no prior treatment with targ . . .